KEVIN MOYNIHAN: Open Payments
NPI 1982709028 · LODI, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$924 in 46 payments from 17 companies in 2025. Trend: 2023 $863 · 2024 $950 · 2025 $924
Food & beverage: $924
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 12 | $225 |
| Novo Nordisk Inc | 6 | $119 |
| Regeneron Healthcare Solutions, Inc. | 3 | $81 |
| Lilly USA, LLC | 3 | $74 |
| Exact Sciences Corporation | 3 | $55 |
| Phathom Pharmaceuticals, Inc. | 4 | $54 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $51 |
| GlaxoSmithKline, LLC. | 2 | $51 |
| Organogenesis Inc. | 2 | $41 |
| Novartis Pharmaceuticals Corporation | 1 | $28 |
Products named: AIRSUPRA, DUPIXENT, MOUNJARO, FARXIGA, Ozempic, VOQUEZNA, BREZTRI, JARDIANCE.
Industry payments across CA — which companies pay providers there.
